Epilepsy

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Retrieved on: 
Saturday, December 3, 2022

VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded warrants of the Company (“PFWs”) at a price of $1.249 per PFW (the “PFW Offering”), and (ii) 974,000 units of the Company (“Units”) at a price of $1.25 per Unit (the “Unit Offering”), for aggregate gross proceeds of $2,049,334.

Key Points: 
  • Each Unit is comprised of one common share in the capital of the Company (a Share) and one common share purchase warrant (a Warrant).
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
  • Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain.
  • Bright Minds drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

Retrieved on: 
Friday, December 2, 2022

Webcast / Conference Call Information:

Key Points: 
  • Webcast / Conference Call Information:
    The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the Webinar ID: 815 1815 0021 reference passcode 279853.
  • A replay of the conference call will also be available on Anavexs website for up to 30 days.
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Retrieved on: 
Friday, December 2, 2022

If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.
  • Our pipeline of potential medicines is designed with unique mechanisms of action to address the diverse, underlying pathophysiology of seizures.
  • Our data suggest OV329 to be a potent, next-generation GABA-AT inhibitor with the potential for seizure reduction with chronic, low dosing.
  • Data presented on OV350 support the therapeutic opportunity associated with activating KCC2, a novel target in epilepsy.

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Retrieved on: 
Friday, December 2, 2022

BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022). In addition, the Company is presenting results from the open label extension (OLE) and sub-analyses of data from the XEN1101 Phase 2b X-TOLE clinical trial.

Key Points: 
  • Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We continue to advance our portfolio of neurology-focused programs.
  • We also look forward to meeting with leading epileptologists, including Xenon trial investigators, as well as patient advocacy groups at this important meeting.
  • We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Retrieved on: 
Friday, December 2, 2022

A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.

Key Points: 
  • A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures.
  • Topline data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies showed single and multiple doses of STK-001 up to 45mg were well-tolerated.

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

Retrieved on: 
Friday, December 2, 2022

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.

Key Points: 
  • SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.
  • Data was collected from more than 17,000 patients through Invitae Corporation's Behind the Seizure Program, of which Neurocrine Biosciences is a sponsor.
  • These data (Poster #2.099: Demographic and Clinical Characteristics of Pediatric Patients with SCN8A-related Epilepsies: Results from a No-Charge Epilepsy Gene Panel) will be shared at the AES 2022 Annual Meeting in Nashville, Tennessee, December 26, 2022.
  • Data analysis demonstrated that 36 (0.2%) of the patients had an SCN8A variant that was classified as pathogenic (P) or likely pathogenic (LP).

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Retrieved on: 
Friday, December 2, 2022

ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.

Key Points: 
  • ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • ANAVEX2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.
  • ANAVEX2-73 demonstrated visible improvement in patients with Alzheimers disease.
  • On average, patients, who improved cognitively with ANAVEX2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points.

Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases

Retrieved on: 
Thursday, December 1, 2022

SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae's Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay with plans to include other conditions in the coming months. By engaging with a broader community, Invitae, a leader in the rare pediatric neurodevelopmental field, aims to create value for significantly more patients with rare diseases.

Key Points: 
  • By engaging with a broader community, Invitae, a leader in the rare pediatric neurodevelopmental field, aims to create value for significantly more patients with rare diseases.
  • The Rare Patient Network is a new approach to solving these challenges by directly engaging with the broader community of patients with rare neurodevelopmental conditions.
  • "The Rare Patient Network is a proactive way to empower patients," said Terry Jo Bitchell, PhD., executive director of COMBINEDBrain.
  • The Rare Patient Network enables patients with rare diseases to engage with Invitae's Ciitizen platform to participate in more clinical studies to help advance research without repeated requests from multiple sources for the same information.

SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO

Retrieved on: 
Thursday, December 1, 2022

PANGYO, South Korea, Nov. 30, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Executive Vice President and Head of Bio Investment Center of SK Inc., as the new Chief Executive Officer and President of SK Biopharmaceuticals and its U.S. subsidiary SK Life Science. Mr. Lee will take the helm at the two companies, effective January 1 2023.

Key Points: 
  • Mr. Lee will bring expertise in global new business development and deal-making to further spur the growth of SK Biopharmaceuticals.
  • Dr. Jeong Woo Cho, who had been the CEO of SK Biopharmaceuticals and SK Life Science since 2017, will serve as the President of Future Growth.
  • Also, Mr. Jonggil Choi, Vice President of Bio Investment Center of SK Inc., has been appointed as the Vice President of Global Strategy.
  • At SK Inc., Lee headed the Bio Investment Center, executing key investment deals in line with SK Group's vision to fortify battery, bio, and chip (BBC) businesses as its main growth drivers.

Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022

Retrieved on: 
Wednesday, November 30, 2022

The above listed dates and times are subject to change.

Key Points: 
  • The above listed dates and times are subject to change.
  • Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
  • We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.